A recently published study by Hoberman et al. concluded that 10 days' treatment with amoxicillin-clavulanate tended to reduce the overall symptom burden, the time to symptom resolution, and the rate of persistent signs of acute infection upon otoscopic examination in children aged 6-23 months with acute otitis media (AOM). This study seems to put an end to the controversy between American and European experts concerning the best approach to the treatment of AOM in younger children. However, although treating all children aged less than 2 years with antimicrobial drugs is the lesser of two evils, it is not an ideal solution. Furthermore, the future more widespread use of some already available vaccines against respiratory pathogens could significantly reduce the total number of new episodes of AOM, thus limiting the risk of therapeutic error.
Antibiotic treatment of acute otitis media in pediatrics / S. Esposito, P.G. Marchisio, R. Tenconi, N. Principi. - In: FUTURE MICROBIOLOGY. - ISSN 1746-0913. - 6:5(2011), pp. 485-488. [10.2217/fmb.11.28]
Antibiotic treatment of acute otitis media in pediatrics
S. EspositoPrimo
;P.G. MarchisioSecondo
;N. PrincipiUltimo
2011
Abstract
A recently published study by Hoberman et al. concluded that 10 days' treatment with amoxicillin-clavulanate tended to reduce the overall symptom burden, the time to symptom resolution, and the rate of persistent signs of acute infection upon otoscopic examination in children aged 6-23 months with acute otitis media (AOM). This study seems to put an end to the controversy between American and European experts concerning the best approach to the treatment of AOM in younger children. However, although treating all children aged less than 2 years with antimicrobial drugs is the lesser of two evils, it is not an ideal solution. Furthermore, the future more widespread use of some already available vaccines against respiratory pathogens could significantly reduce the total number of new episodes of AOM, thus limiting the risk of therapeutic error.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.